Offices

We continue to expand our footprint to better service our partners and customers. For more information on CPDC’s locations please contact us.

Capabilities & Services

  • Corporate Headquarters
  • Discovery
  • Radiopharmaceutical R&D Services
  • Radiopharmaceutical Manufacturing Services
  • PET and Therapeutic Radiopharmaceutical Manufacturing & Distribution
  • FDA and Health Canada Inspected Facilities

Capabilities & Services

  • PET Radiopharmaceutical Manufacturing & Distribution
  • Health Canada Inspected Facilities

Capabilities & Services

  • CanProbe Partnership
  • Joint Venture between University Health Network (UHN) and CPDC
  • Radiopharmaceutical Development, Manufacturing & Distribution

Chuck Conroy Appointed CEO of ARTMS

VANCOUVER, British Columbia–ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer. Mr. Conroy brings to ARTMS more than 25 years of experience

CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.

CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.

CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.

Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.

During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.

CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.

CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.

Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.

Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.

ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.

Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.